Noom's New Model Slashes Employer GLP-1 Drug Costs by Nearly 80%

NEW YORK, NY – April 23, 2026 – Digital health company Noom is reporting a seismic shift in the battle against soaring prescription drug costs, announcing that its new SmartRx program is on pace to cut spending on popular GLP-1 weight-loss medications by nearly 80% for its first participating employer. Early data projects the employer's annual spend will plummet to approximately $1.3 million, a stark contrast to the $6.2 million spent in the prior year.

The dramatic savings stem from a direct challenge to the established pharmaceutical supply chain. The program bypasses traditional Pharmacy Benefit Managers (PBMs)—the powerful intermediaries that negotiate drug prices for health plans—to source brand-name medications like Wegovy and Zepbound directly. This move offers a potential lifeline to organizations nationwide struggling to afford the revolutionary but costly anti-obesity drugs.

The Soaring Cost of GLP-1s and the PBM Dilemma

The rapid rise of GLP-1 medications has been a double-edged sword for American employers. While hailed for their effectiveness in treating obesity and related metabolic conditions, their high price tags have sent shockwaves through corporate finance and HR departments. Recent industry reports show GLP-1s accounted for over 10% of total pharmacy claims in 2024, a figure expected to climb. With overall healthcare costs projected to rise by as much as 8% in the coming year, many employers have been forced into difficult decisions, with some cutting coverage for these drugs entirely.

At the center of this financial strain are PBMs, which have long controlled the flow of prescription drugs from manufacturers to patients. These entities traditionally generate revenue through complex rebate negotiations with drug makers and by employing "spread pricing," where they charge health plans more for a drug than they reimburse the pharmacy. This lack of transparency has drawn intense scrutiny and has left many employers feeling powerless over their escalating pharmacy spend.

Noom Health's strategy directly confronts this model. By creating a direct-to-employer (DTE) pathway, often in partnership with logistics and purchasing firms like Waltz Health, it removes the traditional PBM from the equation for these specific drugs. This approach offers employers a clear, fixed price for brand-name medications, eliminating the opaque system of rebates and hidden fees. The result is immediate, predictable savings and greater control over benefit design.

A New Supply Chain for a New Class of Drugs

The SmartRx program represents what many in the industry see as the next evolution in managing high-cost specialty drugs. It functions as a supplemental benefit that integrates with an employer's existing health plan, giving companies the flexibility to design how costs are shared with their employees.

"These early results validate what we've believed from the start — that employers don't have to choose between giving their people access to the most effective weight-loss treatments and managing costs responsibly," said Cody Fair, Chief Commercial Officer at Noom. "As more employers bring SmartRx to their people, we expect the impact to scale significantly by reducing drug costs and building the clinical foundation that makes savings, and outcomes, stick. SmartRx changes the math entirely."

The model is gaining traction beyond just Noom. Pharmaceutical giants Eli Lilly and Novo Nordisk, the makers of the leading GLP-1 drugs, have both announced plans to launch their own direct-to-employer offerings. This growing trend signals a potential market-wide pivot away from the legacy PBM model for high-cost therapies, empowering employers to reclaim control over their healthcare dollars.

Beyond the Price Tag: Integrating Behavior for Better Health and ROI

While the cost savings are grabbing headlines, Noom argues that the financial benefits are intrinsically linked to a more holistic, clinically integrated approach to health. The company's platform was built on a foundation of behavioral science, and its programs aim to address the root causes of chronic conditions rather than just treating downstream symptoms.

Noom Health's just-released white paper, In From Managing Illness to Building Health, makes the case that conditions like obesity, diabetes, and heart disease are often interconnected manifestations of underlying metabolic dysfunction. A fragmented approach that treats each separately, the company contends, is both clinically inefficient and financially unsustainable.

This philosophy is central to Noom Med, the clinical obesity care program that houses SmartRx. The program pairs GLP-1 medication with robust behavioral support through its app, which provides personalized coaching, nutrition guidance, and tools to manage side effects. The company reports that members who combine medication with this behavioral support lose 39% more weight on average than those on medication alone. This enhanced clinical outcome is critical for long-term health and medication adherence, a significant challenge in real-world settings where discontinuation rates can be high.

"What makes SmartRx clinically meaningful isn’t just the price point — it’s that medication access and behavior change are fully integrated into one seamless experience,” said Jennifer Jones, Director of Clinical Solutions Architect at Noom. “Members aren’t navigating two separate systems. That continuity is what drives real outcomes, and what we’re seeing in the data reflects that.”

This integrated model's value has been quantified by Accorded, an independent actuarial firm, which validated that the Noom Med program can deliver a 4.1x return on investment over three years for employers compared to a scenario with uncontrolled GLP-1 spending. By improving health outcomes and ensuring patients stay on their therapy longer, the program promises not only to cut drug acquisition costs but also to reduce overall medical expenses in the long run.

A Market in Flux as Competitors Respond

Noom is not operating in a vacuum. The entire healthcare industry is scrambling to adapt to the GLP-1 phenomenon. In addition to drug manufacturers going direct, other digital health companies like Ro and Omada Health are offering their own programs that combine medication with virtual support. Even traditional insurers and their PBMs are launching new initiatives. Cigna's EncircleRx and Elevance Health's digital weight management programs are examples of incumbents adapting by building their own integrated solutions to retain employer clients.

This flurry of activity suggests that the future of obesity management will be defined by a convergence of medication, technology, and personalized support. The success of early DTE models like SmartRx is putting pressure on all players to deliver greater transparency, demonstrable cost savings, and superior clinical results. For employers and their employees, this intensifying competition may finally pave the way for a more affordable and sustainable path to managing metabolic health.